Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Michelino De Laurentiis Mark Clemons Seock-Ah Im Hiroji Iwata Norikazu Masuda |
| Publication date | September 18, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |